SavedAdd your journal

Journals / Türk Yoğun Bakım Dergisi / 2015 / Cilt: 13 - Sayı: 2

Yüksek Doz SSRI Alımına Bağlı Gelişen Serotonin Sendromu

Serotonin Syndrome Due to Overdose ıntake of SSRI

Yavuz ORAK
Sevgi AKBULUT
Pages
79–82
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case is a 25-year-old female patient who attempted suicide by ingesting an overdose of her prescription medications: 60 units of 100- mg Faver (Fluvoxamine), 20 units of 50-mg Setral (Setraline), and 10 units of 20-mg Paxil (Paroxetine).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Serotonin syndrome is a drug side effect resulting from serotonergic hyperactivity.
📊
Key Findings & Data:The severity of its symptoms can be mild and overlooked and sometimes it may cause life-threatening serious consequences.
💡
Conclusion & Impact:This case is a 25-year-old female patient who attempted suicide by ingesting an overdose of her prescription medications: 60 units of 100- mg Faver (Fluvoxamine), 20 units of 50-mg Setral (Setraline), and 10 units of 20-mg Paxil (Paroxetine).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Serotonin syndrome is a drug side effect resulting from serotonergic hyperactivity. The severity of its symptoms can be mild and overlooked and sometimes it may cause life-threatening serious consequences. This syndrome is caused by the administration of one or more drugs having serotonergic activity. This case is a 25-year-old female patient who attempted suicide by ingesting an overdose of her prescription medications: 60 units of 100- mg Faver (Fluvoxamine), 20 units of 50-mg Setral (Setraline), and 10 units of 20-mg Paxil (Paroxetine).

Özet

Serotonin sendromu serotonerjik aşırı etkinlik sonucu oluşan bir ilaç yan etkisidir. Hafif şiddette olup gözden kaçabildiği gibi hayatı tehdit eden ciddi sonuçları olabilmektedir. Serotonerjik etkili bir veya daha fazla ilacın bir arada kullanılması bu sendroma yol açar (Dokuz Eylül). Buradaki olgu 25 yaşında kadın hasta olup intihar amaçlı yüksek doz 60 adet 100 mg Faver (Fluvoxamine), 20 adet 50 mg Setral (Setraline), 10 adet 20 mg Paxil (Paroxetine)

🔖

Cite This Article

ORAK, Y., AKBULUT, S. (2015). Yüksek Doz SSRI Alımına Bağlı Gelişen Serotonin Sendromu. Türk Yoğun Bakım Dergisi, Cilt: 13 - Sayı: 2, 79–82. https://ajindex.com/articles/327782

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Auster R. Sertraline: a new antidepressant. Am Fam Physician 1993;48:311-4
  2. Murdoch D, McTavish D. Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder. Drugs 1992;44:604-24
  3. Kelsey JE, Nemeroff CB. Fluvoxamine. In: Sadock BJ, Sadock VA, editors. Comprehensive Textbook of Psychiatry Volume II. Philedelphia: Lippincott Williams&Wilkins 2000 p: 2444-6
  4. Badawy M, Maffei FA. Toxicity; Selective Serotonin Reuptake Inhibitor. May 2006. Available at http://www.emedicine.com/ PED/topic2786.htm 05.03.2006
  5. Brown TM, Skop BP, Mareth TR. Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 1996;30:527-33
  6. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-20
  7. Looper KJ. Potential medical and surgical complications of serotonergic antidepressant medications. Psychosomatics 2007;48:1-9
  8. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13
  9. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter serotonin toxicity criteria: simple and accurate diagnositic decision rules for serotonin toxicity. QJM 2003;96:635-42
  10. Radomski JW, Dursun SM, Reveley MA, Kutcher SP. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnositic criteria. Med Hypotheses 2000:55:218-24
  11. Jones D, Story DA. Serotonin syndrome and the anaesthetist. Anaesth Intensive Care 2005;33:181-7
  12. Gupta S, Nihalani ND. Neuroleptic malignant syndrome: a primary care perspective. Prim Care Companion J Clin Psychiatry 2004;6:191-4
  13. Nierenberg DW, Semprebon M. The central nervous system serotonin syndrome. Clin Pharmacol Ther 1993;53:84-8
  14. Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA. 2005;293:2918-24
  15. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13
  16. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol 1998;12:482-91
  17. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychoparmacol 1997;17:208-21
  18. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995;45:219-23
  19. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract 1999;49:871-4.